-
-
-
-
-
-
-
Novocure (NVCR) Misses Q1 EPS by 13c, provides guidance
-
-
-
-
-
-
-
Novocure to Participate in 2026 Leerink Global Healthcare Conference
-
-
-
-
-
-
-
NovoCure reports $655 million 2025 revenue, up 8% from prior year
-
-
-
-
-
-
-
Novocure (NVCR) Tops Q3 EPS by 9c
-
-
-
-
-
-
-
NovoCure's Optune Lua receives approval in Japan for lung cancer treatment
-
-
-
-
-
-
-
Novocure (NVCR) Tops Q2 EPS by 2c
-
-
-
-
-
-
-
Novocure Reports First Quarter 2025 Financial Results
-
1,201,887 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

